MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.160
+0.040
+1.89%
After Hours: 2.230 +0.07 +3.24% 17:59 05/07 EDT
OPEN
2.160
PREV CLOSE
2.120
HIGH
2.270
LOW
2.154
VOLUME
475.43K
TURNOVER
--
52 WEEK HIGH
6.98
52 WEEK LOW
2.110
MARKET CAP
122.30M
P/E (TTM)
-1.8353
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 2d ago
Meniere Disease Drugs Market Size 2021 Global Trend, Top Manufacturers, Regions Analysis and Leading 20 Countries and Forecast by 2027
The Express Wire · 2d ago
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, May 04, May 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical...
GlobeNewswire · 5d ago
Otonomy, AGTC To Present Preclinical Proof-Of-Concept Results For OTO-825 Gene Therapy At ASGCT Annual Meeting
Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept data for
Benzinga · 04/28 12:00
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public off...
GlobeNewswire · 04/19 12:30
Global Meniere Disease Drugs Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Meniere Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market...
Heraldkeepers · 04/15 16:29
OTIC, HLIT, VNET and TLSA among after-hours movers
Gainers: [[OTIC]] +10.4%. [[ASRV]] +5.2%. [[ANGI]] +3.3%. [[HLIT]] +2.7%. [[GDS]] +2.7%.Losers: [[VNET]] -7.7%. [[IMMP]] -5.1%. [[MIND]] -4.6%. [[AMRN]] -4.1%. [[TLSA]] -3.2%.
Seekingalpha · 04/12 21:42
8-K: OTONOMY, INC.
(EDGAR Online via COMTEX) -- false 0001493566 0001493566 2021-04-07 2021-04-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/09 21:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OTIC. Analyze the recent business situations of Otonomy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OTIC stock price target is 5.63 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 93
Institutional Holdings: 35.73M
% Owned: 63.10%
Shares Outstanding: 56.62M
TypeInstitutionsShares
Increased
22
3.06M
New
20
2.44M
Decreased
22
3.54M
Sold Out
9
2.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Jay Lichter
President/Chief Executive Officer/Director
David Weber
Chief Financial Officer
Paul Cayer
Chief Technology Officer
Robert Savel
Independent Director
James Breitmeyer
Independent Director
Vickie Capps
Independent Director
Ciara Kennedy
Independent Director
Iain McGill
Independent Director
Theodore Schroeder
No Data
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTIC stock methods without spending real money on the virtual paper trading platform.